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Malignant hyperthermia is a rare, 
autosomal dominant genetic disorder of 
the skeletal muscle that causes a life 
threatening hypermetabolic crisis. The 
people who are susceptible to MH have a 
gene mutation in the ryanodine receptor 
subtype 1 (RYR-1) gene which is found 
in all skeletal muscle. This gene encodes 
the calcium ion channel in skeletal 
muscle and is responsible for calcium 
release within myocytes. The RYR-1 is 
also the binding site for inhaled 
anesthetics and dantrolene (Cain, Riess, 
Gettrust, & Novalija, 2014, p. 302). When 
triggering agents such as volatile 
(inhaled) anesthetics and depolarizing 
muscle relaxants are administered to an 
individual with an abnormal RYR-1 gene, 
there is a prolonged opening of the 
altered RYR-1 receptor and an 
uncontrolled intracellular calcium 
release from the skeletal muscle 
sarcoplasmic reticulum into the cytosol. 
This causes a state of intense, sustained 
skeletal muscle contraction and rigidity 
which, in turn, causes increased 
sympathetic activity, oxygen 
consumption, and the production of 
carbon dioxide and heat from the rapid 
use of ATP (Hirshey Dirksen et al., 2013,  
p. 331). The contracted cells eventually 
deplete the oxygen and ATP and begin 
anaerobic metabolism which produces 
lactic acid and ultimately causes cellular 
death and destruction. Potassium, as 
well as other electrolytes (such as 
calcium, phosphate, and magnesium), 
creatine kinase(CK), and myoglobin then 
leak into the bloodstream as a result of 
the damaged cell membranes (Seifert et 
al., 2014, p. 195-196). 
Malignant hyperthermia is a very 
rare occurrence and only occurs 
approximately once in every 3,000 to 
50,000 procedures where volatile 
anesthetics are administered (Dirksen 
et al., 2013, p. 330). It is of importance, 
though, because it can progress quickly 
to a life threatening situation and is a 
medical emergency. Because it is rare, 
many nurses are unprepared to care for 
a patient experiencing MH. The specifics 
about the signs and symptoms, 
diagnosis, treatment, and location of 
MH emergency supplies should be 
reviewed frequently by personnel that 
may encounter it (Hirshey Dirksen, 
2013, p. 333). The areas where MH may 
occur are vast which means nurses of 
all specialties need to review this 
information at a minimum of each year 
to give the patient experiencing MH a 
chance for the best outcome. Education 
and simulation are integral parts of MH 
preparedness. 
Malignant hyperthermia (MH) is a 
potentially life threatening disorder that 
occurs following exposure to certain 
inhaled anesthetics such as halothane, 
isoflurane, sevoflurane, desflurane, 
enflurane, ether, and methoxyflurane 
alone or in combination with the 
depolarizing muscle relaxant, 
succinylcholine (Seifert,, Wahr, Pace, 
Cochrane, & Bagnola, 2014, p. 189). 
Patients experiencing malignant 
hyperthermia may progress to death if it 
is not recognized and treated early. 
Patient outcomes improve the earlier an 
intervention is given. Malignant 
hyperthermia is not a common condition 
and, therefore, nurses are frequently 
unfamiliar with the common signs, 
symptoms, and treatments. Malignant 
hyperthermia can occur in a variety of 
settings where these medications are 
used such as the operating room, post 
anesthesia recovery unit (PACU), 
emergency department, interventional 
radiology, labor and delivery, intensive 
care units, dental offices, and ambulatory 
surgery centers such as surgery centers 
and office based facilities, hence, nurses 
of all specialties may encounter MH 
(Hirshey Dirksen, Van Wicklin, Mashman, 
Neiderer, & Merritt, 2013, p. 332). 
Recurrent education and simulation with 
staff that work with patients receiving 
possible triggering agents would improve 
patient outcomes when they are faced 
with malignant hyperthermia 
emergencies. The purpose of this 
scholarly project is to provide education 
to nurses regarding malignant 
hyperthermia in hopes that it will 
increase their knowledge on the subject 
and prepare them for the medical 
emergency of malignant hyperthermia. 
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Significance of Pathophysiology 
 
 
Signs and Symptoms 
• Hypercarbia 
• Tachycardia 
• Masseter spasm 
• Flushed skin 
• Cardiac dysrhythmias 
• Generalized muscle rigidity 
• Tachypnea 
• Hyperthermia 
• Hypoxia 
• Acidosis 
• Coagulopathy 
 
 
 
lobortis temporibus in usu? 
The goal of treatment of malignant 
hyperthermia is to reverse the 
hypermetabolic state and prevent the 
potentially lethal consequences of MH. 
The likelihood of a positive outcome 
after diagnosis of MH improves with 
expeditious treatment. If MH is not 
treated rapidly, the mortality rate is 
high. The most effective treatment for 
MH is the administration of dantrolene 
sodium. The mortality rate from MH 
used to be as high as 80%, but since the 
discovery of dantrolene in 1975, it is 
now down to 5% (Hirshey Dirksen et 
al., 2013, p. 330). Dantrolene is a 
specific ryanodine receptor antagonist 
and reverses the MH related muscle 
contractions by decreasing the calcium 
in muscle cells (Seifert et al., 2014, p. 
192). The longer time that elapses 
between the onset of MH and the first 
dose of dantrolene results in an 
increase in complications associated 
with MH. It is well known that the 
preparation of dantrolene is difficult. 
Some of the  difficulties with dantrolene 
preparation are that it requires large 
quantities of diluents to be mixed with 
large quantities of the medication and it 
requires complicated medication 
calculations. The required dose of 
dantrolene is 2.5 mg/kg rapidly 
through a large bore IV every 5 minutes 
and repeat until symptoms subside or a 
maximum dose of 30 mg/kg has been 
reached. Dantrolene comes in 20 mg 
vials and must be mixed with 60 ml 
sterile water (Seifert et al., 2014, p. 
192-194). For a patient who weighs 
100 kg, the initial dose of dantrolene.  
would be 250 mg. That would require 12.5 
vials of dantrolene to be mixed and a total of 
750 ml sterile water. If this medication 
preparation must be done every five 
minutes, it can become time consuming and 
difficult to calculate. It may take several 
nurses mixing dantrolene at the same time 
to get the first critical dose in a timely 
manner. In a rare situation like MH, this skill 
is not second nature and must be practiced 
to be effective in an emergency. Another 
obvious treatment of MH is to stop the 
volatile anesthetic and either abort the 
procedure or switch to a non-triggering 
anesthetic. An increase in oxygenation to 
100% FIO2 will help prevent anaerobic 
metabolism, and hyperventilation will 
decrease the excess CO2 build up resulting 
from MH (Seifert et al., 2014, p. 195). Also, 
sodium bicarbonate can be given to treat 
metabolic acidosis, and insulin and calcium 
can be given to treat hyperkalemia (see 
Figure 1). Nurses should be prepared to 
start cooling measures immediately by 
using cooling blankets, gastric lavage, body 
cavity irrigation such as the surgical site, 
and ice packs. Shivering should be avoided, 
though, because it will increase the 
metabolic state. The goal is to keep the 
temperature of the patient with MH lower 
than 39° C [102.2° F] (Cain et al., 2014. p. 
302). Cardiac dysrhythmias should be 
treated with normal ACLS medications, but 
calcium channel blockers should not be 
used because they interact with dantrolene 
at the receptor site (Seifert et al., 2014, p. 
196). After swift and appropriate treatment, 
the patient with MH would hopefully revert 
back to a normal metabolic state with no 
complications. 
Implications for Nursing Care 
Signs and Symptoms 
The significance of the pathophysiology in MH is due to the fatal complications that can 
occur as a result if it goes untreated. Hyperkalemia causes fatal cardiac dysrhythmias 
such as ventricular fibrillation and ventricular tachycardia. Myoglobinemia causes 
renal failure as the excessive CK and myoglobin released into the circulation blocks the 
renal tubules. Other complications, many of which are fatal, from MH include liver 
failure, compartment syndrome from profound muscle swelling, skeletal 
muscle damage, mixed respiratory acidosis or metabolic acidosis, abnormal blood 
coagulation and DIC, internal hemorrhage, neurologic injury, hyperthermia, 
rhabdomyolysis, bowel ischemia, CHF, pulmonary edema, end organ damage, cardiac 
collapse or arrest, and death (Hirshey Dirksen, et al., 2013, p. 333; Seifert et al., 2014, 
p. 189). These clinical signs are results of the inability of the body to maintain the 
increased metabolic demand during a malignant hyperthermia crisis. 
The signs and symptoms of 
malignant hyperthermia usually occur 
within minutes or up to an hour after 
the administration of the triggering 
agent, however, if succinylcholine is 
used in conjunction with an inhaled 
anesthetic, the onset of symptoms is 
generally quicker. It is possible that 
MH may develop up to 36 hours after 
exposure to the triggering agent. The 
signs and symptoms of MH can present 
in any sequence, but there are typically 
three signs that manifest the earliest 
(Cain et al., 2014. p. 302-303). The first 
sign of MH is hypercarbia or an 
unexplained, progressive increase in 
carbon dioxide production. The ETCO2 
can double or triple a normal 
capnography value in MH. The next 
signs that typically manifest are 
masseter (jaw) muscle spasm and 
sinus tachycardia. Other early signs 
include flushed skin, dysrhythmias, 
such as PVC’s and bigeminy, and 
generalized muscle rigidity. 
Hyperthermia is actually a late sign of 
MH despite the name of this disorder. 
The rapid increase in body 
temperature can exceed 43.3° C [109° 
F], and it can increase by 1° C to 2° C 
[1.8° F to 3.6° F] every five minutes 
(Seifert et al., 2014, p. 189). Other late 
signs are metabolic acidosis, hypoxia, 
mottled skin, cyanosis, coagulopathy, 
left ventricular failure evidenced by 
pulmonary edema, rales, and frothy 
sputum, and brown, cola-colored urine 
from rhabdomyolysis. Other possible 
signs and symptoms of MH include 
mixed respiratory acidosis, tachypnea, 
sweating, myoglobinuria, 
hyperkalemia, ventricular tachycardia, 
and ventricular fibrillation (Stewart, 
2014, p. 253-254). MH can recur 
within 24 to 48 hours after the initial 
event, so the patient with MH should 
be monitored for recrudescence, which 
is the recurrence of symptoms after a 
period of remission (Hirshey Dirksen, 
2013, p. 333). 
 
Conclusion 
Figure 1. Medication doses and treatments for malignant hyperthermia. Reprinted from “CRISIS CONSIDERATIONS. Crisis 
Management of Malignant Hyperthermia in the OR”, by P. C. Seifert, J. A. Wahr, A. B. Cochrane, and A. J. Bagnola, 2014, AORN 
Journal, 100(2), p. 198. Copyright 2014 by Elsevier Inc. Reprinted with permission. 
